aviditybiosciences.investorroom.comInvestors | Avidity Biosciences - Overview
aviditybiosciences.investorroom.com Profile
Aviditybiosciences.investorroom.com is a subdomain of Investorroom.com,
which was created on 2000-02-13,making it 24 years ago.
It has several subdomains, such as bbt.investorroom.com
boydgaming.investorroom.com , among others.
Discover aviditybiosciences.investorroom.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
aviditybiosciences.investorroom.com Information
| HomePage size: 79.395 KB |
| Page Load Time: 0.84466 Seconds |
| Website IP Address: 104.17.206.159 |
aviditybiosciences.investorroom.com Similar Website
| Aptiv PLC - Investor Information |
| Owens Corning Investors Overview |
| CI&T Investors Overview |
| First American Financial Corporation - Investors - Overview |
| ICL Group Investors Relations - Overview |
| Maryland Real Estate Investors Association - Maryland Real Estate Investors Association |
| Arcus Biosciences - Investors & Media |
| Western Midstream - Investors - Investors |
| OMNOVA Solutions - Investors - Investors |
| Lam Research Investor Relations - Investors Overview |
| Investors Overview | Tesla, Inc. |
| Investors | Marathon Oil Corporation - Investors |
| Axalta Coating Systems - Investors - Investors Overview |
| Connected Investors | Connect With Real Estate Investors |
| Investors - Toromont Industries Ltd. - Investors |
aviditybiosciences.investorroom.com PopUrls
| avidity biosciences, inc. audit committee charter https://aviditybiosciences.investorroom.com/download/Audit+Charter.pdf |
| Avidity Biosciences https://aviditybiosciences.investorroom.com/download/Comp+Charter.pdf |
| Corporate Presentation January 2021 - Avidity Biosciences https://aviditybiosciences.investorroom.com/download/January+2021+Avidity+Corporate_Presentation.pdf |
| Avidity Corporate Governance Guidelines https://aviditybiosciences.investorroom.com/download/Avidity+Corporate+Governance+Guidelines.pdf |
| Avidity Biosciences https://aviditybiosciences.investorroom.com/download/N%26G+Charter.pdf |
| Optimization of AOC 1001, an antibody-oligonucleotide ... https://aviditybiosciences.investorroom.com/download/20210330+AAN+2021_Avidity+Blitz+Presentation_FINAL.pdf |
| May 2021 - Delivering on the RNA Revolution https://aviditybiosciences.investorroom.com/download/June+2021+Avidity+Corporate+Presentation.pdf |
| Corporate Presentation - January 2021 - Avidity Biosciences https://aviditybiosciences.investorroom.com/download/January+2021+Avidity+Corporate+Presentation.pdf |
| September 2021 - Avidity Biosciences https://aviditybiosciences.investorroom.com/download/September+2021+Avidity+Corporate+Presentation_FINAL.pdf |
| Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial https://aviditybiosciences.investorroom.com/2023-02-28-Avidity-Biosciences-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Recent-Highl |
| Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial https://aviditybiosciences.investorroom.com/2024-02-28-Avidity-Biosciences-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Recent-Highl |
aviditybiosciences.investorroom.com Httpheader
| Date: Tue, 14 May 2024 07:38:49 GMT |
| Content-Type: text/html; charset=UTF-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| X-Frame-Options: SAMEORIGIN |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Cache-Control: public, no-cache |
| Vary: Accept-Encoding |
| CF-Cache-Status: MISS |
| Last-Modified: Tue, 14 May 2024 07:38:49 GMT |
| Server: cloudflare |
| CF-RAY: 88393b1b5a080904-LAX |
aviditybiosciences.investorroom.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-Type"/ |
| content="user-scalable=no, width=device-width, maximum-scale=1, minimum-scale=1" name="viewport"/ |
| content="" name="keywords" |
| content="" name="description" |
| content="summary" name="twitter:card"/ |
| content="Investors | Avidity Biosciences" property="og:site_name"/ |
| content="https://aviditybiosciences.investorroom.com/home" property="og:url"/ |
| content="noindex, nofollow" name="robots"/ |
aviditybiosciences.investorroom.com Html To Plain Text
Avidity Biosciences Search for: Search About Overview Management Board of DirectorsPlatform Overview PublicationsPipeline Patients Investors Overview News, Events and Publications News Releases Events and Presentations Publications SEC Filings Corporate Governance Board of Directors Committee Composition Corporate Governance Documents Stock Information Stock Quote Interactive Chart Investment Calculator Historical Stock Price FAQs Analyst Coverage Contact Careers Search for: ABOUT AVIDITY Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Learn More Stock Performance Nasdaq: RNA NASDAQ RNA INVESTOR CONTACT Geoffrey Grande VP Investor Relations & Corporate Communications investors@aviditybio.com (619) 837-5014 Subscribe to Investor Alerts Corporate Presentation May 2024 Corporate Presentation Events BofA Securities Health Care Conference – Fireside Chat Wednesday, May 15, 2024 11:00am EDT Add to Calendar Set Email Reminder View All Recent News Investor Alerts May 9, 2024 Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE44™ May 8, 2024 Avidity Biosciences to Participate in Upcoming Investor Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced... May 8, 2024 Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 Avidity initiating global Phase 3 HARBOR™ study for delpacibart etedesiran this quarter Delpacibart etedesiran data from MARINA-OLE™ showed reversal of disease progression in multiple... April 22, 2024 Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced... View All © 2024 Avidity Biosciences Explore About Overview Management Board of Directors Platform Pipeline Overview DM1 FSHD DMD Next Indications Patients Investors Overview News, Events and Publications News Releases Events and Presentations Publications SEC Filings Corporate Governance Board of Directors Committee Composition Corporate Governance Documents Stock Information Stock Quote Interactive Chart Investment Calculator Historical Stock Price FAQs Analyst Coverage Contact Careers Contact 10578 Science Center Dr. Suite 125 San Diego, CA 92121 info@aviditybio.com Tel: 858-401-7900 Follow Legal Terms of Use Privacy Policy Patents PO Terms & Conditions MENU About Overview Management Board of Directors Platform Overview Publications Pipeline Overview DM1 FSHD DMD Next Indications Expanded Access Patients Investors Overview News, Events and Publications News Releases Events and Presentations Publications SEC Filings Corporate Governance Board of Directors Committee Composition Corporate Governance Documents Stock Information Stock Quote Interactive Chart Investment Calculator Historical Stock Price FAQs Analyst Coverage Contact...
aviditybiosciences.investorroom.com Whois
Domain Name: INVESTORROOM.COM Registry Domain ID: 19764015_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2024-02-09T06:12:35Z Creation Date: 2000-02-13T16:35:21Z Registry Expiry Date: 2025-02-13T16:35:21Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: DOM.NS.CLOUDFLARE.COM Name Server: MIA.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T12:50:47Z <<<